Boehringer Ingelheim, a research-driven biopharmaceutical company, agreed to acquire Avexxa Biologics, a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. Financial terms were not disclosed. “The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of targeting intracellular antigens. Their cutting-edge know-how and technologies for antigen discovery and novel antibody generation strongly complement the current approaches we have been applying successfully to enable immune-targeting of cancer cells,” Clive R. Wood, Boehringer Ingelheim Senior Vice President.